KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis of the SURMOUNT-1 Trial.

Yasushi Ishigaki, Masamichi Yamada, Tomotaka Shingaki, Tomonori Oura, Iichiro Shimomura

Obesity (Silver Spring) 34(3) 608-621

PMID41612966
PMCIDPMC12933229
DOI10.1002/oby.70131
发表日期2026-01-30
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:FIGURE 1:CONSORT/入组流程图;FIGURE 2:AI 判定为 other;FIGURE 3:非 KM 图。
摘要

摘要

OBJECTIVE: This prespecified subpopulation analysis aimed to assess the efficacy and safety of once-weekly tirzepatide versus placebo alongside lifestyle intervention in Japanese adults with obesity or overweight. METHODS: Data from 102 Japanese adults in the SURMOUNT-1 trial with BMI ≥ 30 kg/m2 or ≥ 27 kg/m2 and ≥ 1 weight-related comorbidity were analyzed. Coprimary endpoints were mean percent change in body weight and the proportion of participants who achieved ≥ 5% body weight reduction at week 72. RESULTS: Participants in the tirzepatide 5-, 10-, and 15-mg groups had a statistically significantly greater (all p < 0.001) least squares mean (standard error) percent change in body weight compared with those in the placebo group: -12.0% (1.7%), -22.4% (1.7%), -22.1% (1.6%), and -0.3% (1.6%), respectively. Overall, 91.7%, 100%, and 96.6% of participants in the tirzepatide 5-, 10-, and 15-mg groups, respectively, had ≥ 5% weight reduction at week 72, compared with 15.4% in the placebo group. Significant improvements in cardiometabolic measures were also observed with tirzepatide at week 72 compared to placebo. No new safety concerns were identified. CONCLUSIONS: Once-weekly treatment with tirzepatide demonstrated significant reductions in body weight and prespecified cardiometabolic measures compared with placebo in Japanese adults with obesity or overweight. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT04184622 https://clinicaltrials.gov/study/NCT04184622.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1Participant disposition. Flow diagram of Japanese participants from the SURMOUNT‐1 trial included in the analysis (one study site was excluded due to a regulatory noncompliance issue). ITT, intention‐to‐treat; N , number of participants in the analysis population.
非 KM Figure
FIGURE 2Effect of tirzepatide on body weight and waist circumference. Japanese participants from the SURMOUNT‐1 trial were treated with once‐weekly tirzepatide (5, 10, or 15 mg) or placebo. Data are shown for the modified intention‐to‐treat population (efficacy analysis set). For each parameter, only participants with a nonmissing baseline value and at least one nonmissing postbaseline value were included in the analysis. (A) Percent change in body weight from baseline to week 72 derived from an MMRM analysis. Data are shown as LSM (SE). Change in body weight was statistically significantly lower ( p < 0.001) from week 4 to week 72 for all tirzepatide treatment groups versus placebo. (B) Proportion of participants achieving body weight reduction thresholds. Results are from logistic regression with missing values imputed by an MMRM analysis. P values represent statistically significant differences in the tirzepatide treatment groups versus placebo. (C) Change in waist circumference from baseline to week 72. Data are shown as LSM (SE). Postbaseline data are from an MMRM analysis. LSM, least squares mean; MMRM, mixed model for repeated measures. * p < 0.05 versus placebo, ** p < 0.01 versus placebo, *** p < 0.001 versus placebo. [Color figure can be viewed at wileyonlinelibrary.com ]
非 KM Figure
FIGURE 3Effect of tirzepatide on lipids and blood pressure. Data are shown for the modified intention‐to‐treat population (efficacy analysis set). For each parameter, only participants with a nonmissing baseline value and at least one nonmissing postbaseline value were included in the analysis. (A) Mean percent change in lipids at week 72 following once‐weekly treatment with tirzepatide (5, 10, or 15 mg) or placebo. Log‐transformed postbaseline data were analyzed with an MMRM. (B) Mean change from baseline to week 72 in SBP using pooled data for the tirzepatide 5‐, 10‐, and 15‐mg groups versus placebo. Data are shown as LSM (SE). Postbaseline data were analyzed with an MMRM. (C) Mean change from baseline to week 72 in DBP using pooled data for the tirzepatide 5‐, 10‐, and 15‐mg groups versus placebo. Data are shown as LSM (SE). Postbaseline data were analyzed with an MMRM. DBP, diastolic blood pressure; HDL‐C, high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; LSM, least squares mean; MMRM, mixed model for repeated measures; SBP, systolic blood pressure; VLDL‐C, very low‐density lipoprotein cholesterol. * p < 0.05 versus placebo, ** p < 0.01 versus placebo, *** p ≤ 0.001 versus placebo. [Color figure can be viewed at wileyonlinelibrary.com ]
非 KM Figure